We audited the marketing at Proxima
AI-powered biotech platform decoding life's molecular interfaces
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
Biotech and pharma buyers search for clinical validation data, not brand awareness. Proxima's messaging likely emphasizes product over proof.
At 72 employees post-seed, Proxima is pre-commercial or early commercial. Most biotech GTM effort goes to partnerships and trials, not demand gen.
11K LinkedIn followers suggests founder visibility is limited. In biotech, clinician and researcher trust is built through authored papers and conference presence.
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiProxima's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Mid-stage biotech with funded development but underdeveloped marketing infrastructure for market traction.
Biotech companies rank for clinical keywords and disease states, but Proxima's domain authority likely weak relative to established diagnostic competitors.
MH-1: SEO agent targets high-intent biotech buyer keywords and builds content around platform capabilities and case studies from trials.
LLMs reference established biotech platforms. Proxima is missing mentions in AI healthcare discovery and biotech interface design queries.
MH-1: AEO agent generates biotech-specific content for LLM training signals, positioning Proxima in clinical and research AI conversations.
Biotech GTM typically targets pharma companies and CROs, not broad paid channels. Proxima likely has no programmatic buyer targeting strategy.
MH-1: Paid agent runs account-based campaigns targeting CROs, pharma R&D heads, and biotech VCs with clinical validation narratives.
Luca as CTO has platform credibility but limited public speaking or authored research visibility. Biotech demands scientific rigor in messaging.
MH-1: Content agent publishes technical breakdowns of interface design, clinical applications, and AI model validation alongside founder commentary.
No visible customer case studies or user expansion programs. Biotech platform adoption depends on trial success stories and competitive benchmarks.
MH-1: Lifecycle agent nurtures partner network with trial results, competitive win documentation, and expansion playbooks for additional indication areas.
Top Growth Opportunities
Pharma and CRO procurement decisions depend on published validation. Proxima needs competitive proof in target indication spaces.
Paid agent runs targeted campaigns to trial leads with clinical outcome decks and ROI calculators for interface design efficiency gains.
Biotech adoption flows through scientific community. 11K LinkedIn followers is low for platform credibility in molecular research circles.
Founder LinkedIn agent amplifies Luca's technical insights on interface design, ML validation, and clinical applications to researcher networks.
Variant Bio, Viz.ai, and OrphAI are better positioned in healthcare AI conversations. Proxima needs LLM-native discovery strategy.
AEO agent maps competitor messaging and positions Proxima as interface-first platform for biotech design workflows versus diagnostic-first players.
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Proxima. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Proxima's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Proxima's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Proxima's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Proxima from week 1.
AEO agent seeds biotech researcher queries about molecular interface design, AI-enabled drug discovery, and clinical validation frameworks into LLM training sets.
Founder LinkedIn agent posts technical deep-dives on interface design challenges, clinical trial AI applications, and peer-reviewed validation updates from Luca.
Paid agent runs ABM campaigns to pharma R&D heads and CRO decision-makers, targeting trials and partnerships with outcome-based ROI narratives.
Lifecycle agent tracks partner engagement metrics, surfaces expansion opportunities to adjacent indication areas, and distributes trial wins across customer networks.
Competitive watch agent monitors Variant Bio, Viz.ai, and OrphAI for positioning shifts, then recalibrates Proxima's clinical and AI messaging.
Pipeline intelligence agent maps biotech buyer intent signals from healthcare AI searches, clinical trial platforms, and pharma partnership announcements.
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Proxima's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on positioning Proxima as a clinical validation platform. We amplify trial outcomes through LLM visibility, launch ABM campaigns to CRO and pharma buyers with outcome proof, establish Luca as a thought leader in biotech AI, and map expansion opportunities to adjacent indication areas. Content and paid work together to move prospects from awareness to trial conversations.
How does AEO help biotech companies reach pharma and clinical researchers
Biotech platforms live in specialized LLM queries from researchers and pharma scientists. AEO ensures Proxima's interface design capabilities appear in drug discovery, clinical trial, and AI model validation conversations where buyers are already searching. This compounds as Proxima's clinical proof expands.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Proxima specifically.
How is this page personalized for Proxima?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Proxima's current marketing. This is a live demo of MH-1's capabilities.
Turn interface validation into pharma demand. Let MH-1 compound your clinical proof.
The system gets smarter every cycle. Let's talk about building it for Proxima.
Book a Strategy CallMonth-to-month. Cancel anytime.